OPBP-1 

OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research^[1].

1477.60

C₆₄H₉₂N₂₀O₁₉S

d-(Gly-Gln-Ser-Glu-His-His-Met-Arg-Val-Tyr-Ser-Phe)

d-(GQSEHHMRVYSF)

O=C(N[C@H](CCC(N)=O)C(N[C@H](CO)C(N[C@H](CCC(O)=O)C(N[C@H](CC1=CNC=N1)C(N[C@H](CC2=CNC=N2)C(N[C@H](CCSC)C(N[C@H](CCCNC(N)=N)C(N[C@H](C(C)C)C(N[C@H](CC3=CC=C(C=C3)O)C(N[C@H](CO)C(N[C@H](CC4=CC=CC=C4)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li W, et al. An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy[J]. Journal of Controlled Release, 2021, 334: 376-388.  [Content Brief]